In the following sections, we examine how disturbances in the RKIP–YY1 axis contribute to the pathogenesis of obesity, diabetes, and atherosclerosis, and highlight emerging opportunities for targeted therapeutic modulation. This evidence concerns the gene PEBP1 and obesity disorder.